National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19
Copyright © 2022, Author(s)..
More than a year after the onset of the coronavirus disease pandemic in 2019, the disease remains a major global health issue. During this time, health organizations worldwide have tried to provide integrated treatment guidelines to control coronavirus disease 2019 (COVID-19) at different levels. However, due to the novel nature of the disease and the emergence of new variants, medical teams' updating medical information and drug prescribing guidelines should be given special attention. This version is an updated instruction of the National Research Institute of Tuberculosis and Lung Disease (NRITLD) in collaboration with a group of specialists from Masih Daneshvari Hospital in Tehran, Iran, which is provided to update the information of caring clinicians for the treatment and care of COVID-19 hospitalized patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Iranian journal of pharmaceutical research : IJPR - 21(2022), 1 vom: 07. Dez., Seite e123947 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Acute Respiratory Distress Syndrome (ARDS) |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.5812/ijpr.123947 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342864114 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342864114 | ||
| 003 | DE-627 | ||
| 005 | 20231226015109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5812/ijpr.123947 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342864114 | ||
| 035 | |a (NLM)35765502 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mirenayat, Maryam Sadat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a National Research Institute of Tuberculosis and Lung Disease (NRITLD) Protocol for the Treatment of Patients with COVID-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Author(s). | ||
| 520 | |a More than a year after the onset of the coronavirus disease pandemic in 2019, the disease remains a major global health issue. During this time, health organizations worldwide have tried to provide integrated treatment guidelines to control coronavirus disease 2019 (COVID-19) at different levels. However, due to the novel nature of the disease and the emergence of new variants, medical teams' updating medical information and drug prescribing guidelines should be given special attention. This version is an updated instruction of the National Research Institute of Tuberculosis and Lung Disease (NRITLD) in collaboration with a group of specialists from Masih Daneshvari Hospital in Tehran, Iran, which is provided to update the information of caring clinicians for the treatment and care of COVID-19 hospitalized patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute Respiratory Distress Syndrome (ARDS) | |
| 650 | 4 | |a Clinical Management | |
| 650 | 4 | |a Coronavirus Disease | |
| 650 | 4 | |a SARS-COV-2 | |
| 650 | 4 | |a Treatment Guidelines | |
| 700 | 1 | |a Abedini, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Kiani, Arda |e verfasserin |4 aut | |
| 700 | 1 | |a Eslaminejad, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Adimi Naghan, Parisa |e verfasserin |4 aut | |
| 700 | 1 | |a Malekmohammad, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Heshmatnia, Jalal |e verfasserin |4 aut | |
| 700 | 1 | |a Nadji, Seyed Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Idani, Esmaeil |e verfasserin |4 aut | |
| 700 | 1 | |a Zahiri, Reyhaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Lookzadeh, Somayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Sheikhzade, Hakimeh |e verfasserin |4 aut | |
| 700 | 1 | |a Dastan, Farzaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Porabdollah Toutkaboni, Mihan |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Mitra Sadat |e verfasserin |4 aut | |
| 700 | 1 | |a Askari, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Marjani, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Moniri, Afshin |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemian, Seyed Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Farzanegan, Behrooz |e verfasserin |4 aut | |
| 700 | 1 | |a Abtahian, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Yassari, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Mansouri, Nazanin |e verfasserin |4 aut | |
| 700 | 1 | |a Mansouri, Davood |e verfasserin |4 aut | |
| 700 | 1 | |a Vasheghani, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Mansourafshar, Babak |e verfasserin |4 aut | |
| 700 | 1 | |a Mokhber Dezfoli, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Soleimani, Salman |e verfasserin |4 aut | |
| 700 | 1 | |a Seifi, Sharareh |e verfasserin |4 aut | |
| 700 | 1 | |a Naghashzadeh, Farah |e verfasserin |4 aut | |
| 700 | 1 | |a Fakharian, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Varahram, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Jamaati, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Zali, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Velayati, Ali Akbar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Iranian journal of pharmaceutical research : IJPR |d 2010 |g 21(2022), 1 vom: 07. Dez., Seite e123947 |w (DE-627)NLM232822573 |x 1726-6890 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2022 |g number:1 |g day:07 |g month:12 |g pages:e123947 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5812/ijpr.123947 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2022 |e 1 |b 07 |c 12 |h e123947 | ||